Loading…
BIO-CIPROFLOXACIN is a brand name for Ciprofloxacin, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Bio-CIPROFLOXACIN (ciprofloxacin tablet) may be indicated for the treatment of patients with the following infections caused by susceptible strains of the indicated microorganisms: Respiratory Tract Infections Acute exacerbation of chronic bronchitis caused by: Haemophilus influenzae Moraxella catarrhalis Acute…
Verbatim from this product's HC label. Tap a section to expand.
5 MISSED DOSE 03/2025 7 WARNINGS AND PRECAUTIONS 03/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES………………………………………………………………………………………………2 TABLE OF CONTENTS…………………………………………………………………………………………………………………2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1. INDICATIONS ...................................................................................................................... 1 Pediatrics ...............................................................................................................................
2 Geriatrics ............................................................................................................................... 7 2. CONTRAINDICATIONS .........................................................................................................
7 3. SERIOUS WARNINGS AND PRECAUTIONS BOX..................................................................... 8 4. DOSAGE AND ADMINISTRATION ......................................................................................... 1 Dosing Considerations...........................................................................................................
2 Recommended Dose and Dosage Adjustment Adults .......................................................... 4 Administration ....................................................................................................................
5 Missed Dose ........................................................................................................................ 11 5. OVERDOSAGE ...................................................................................................................
11 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ...................................... 122 7. WARNINGS AND PRECAUTIONS ........................................................................................ 1 Special Populations .............................................................................................................
17 8. ADVERSE REACTIONS ........................................................................................................ 1 Adverse Reaction Overview ................................................................................................
). Bio-CIPROFLOXACIN Page 13 of 64 Aortic Aneurysm and Aortic Dissection Epidemiologic studies report an increased risk of aortic aneurysm and aortic dissection after intake of fluoroquinolones, particularly in the older population.
, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet’s disease, hypertension, atherosclerosis). In case of sudden severe abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.
, glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. SEVERE CASES OF HYPOGLYCEMIA RESULTING IN COMA OR DEATH HAVE BEEN REPORTED. If a hypoglycemic reaction occurs, discontinue Bio-CIPROFLOXACIN immediately and initiate appropriate therapy (see 8 ADVERSE REACTIONS and
03/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES………………………………………………………………………………………………2 TABLE OF CONTENTS…………………………………………………………………………………………………………………2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1. INDICATIONS ...................................................................................................................... 1 Pediatrics ...............................................................................................................................
2 Geriatrics ............................................................................................................................... 7 2. CONTRAINDICATIONS .........................................................................................................
7 3. SERIOUS WARNINGS AND PRECAUTIONS BOX..................................................................... 8 4. DOSAGE AND ADMINISTRATION ......................................................................................... 1 Dosing Considerations...........................................................................................................
2 Recommended Dose and Dosage Adjustment Adults .......................................................... 4 Administration ....................................................................................................................
5 Missed Dose ........................................................................................................................ 11 5. OVERDOSAGE ...................................................................................................................
11 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ...................................... 122 7. WARNINGS AND PRECAUTIONS ........................................................................................ 1 Special Populations .............................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ciprofloxacin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
2 Clinical Trial Adverse Reactions ........................................................................................... 3 Less Common Clinical Trial Adverse Reactions....................................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data...................................................................................................................................... 5 Post-Market Adverse Reactions ..........................................................................................
20 9. DRUG INTERACTIONS ........................................................................................................ 2 Drug Interactions Overview.................................................................................................
3 Drug-Behavioral Interactions .............................................................................................. 4 Drug-Drug Interactions .......................................................................................................
5 Drug-Food Interactions...................................................................................................... 6 Drug-Herb Interactions .....................................................................................................
7 Drug-Laboratory Test Interactions .................................................................................... 277 10. CLINICAL PHARMACOLOGY ...........................................................................................
1 Mechanism of Action ...................................................................................................... 3 Pharmacokinetics ............................................................................................................
277 11. STORAGE, STABILITY AND DISPOSAL .............................................................................. 333 12. SPECIAL HANDLING INSTRUCTIONS................................................................................
34 13. PHARMACEUTICAL INFORMATION ............................................................................... 344 14. CLINICAL TRIALS ............................................................................................................
2 Comparative Bioavailability Studies................................................................................ 355 15. MICROBIOLOGY ............................................................................................................
355 16. NON-CLINICAL TOXICOLOGY .......................................................................................... 399 17. SUPPORTING PRODUCT MONOGRAPHS ........................................................................ 433 PATIENT MEDICATION INFORMATION ................................................................................
444 Bio-CIPROFLOXACIN Page 4 of 64 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS Bio-CIPROFLOXACIN (ciprofloxacin tablet) may be indicated for the treatment of patients with the following infections caused by susceptible strains of the indicated microorganisms: Respiratory Tract Infections Acute exacerbation of chronic bronchitis caused by: Haemophilus influenzae Moraxella catarrhalis Acute pneumonia caused by: […]
17 8. ADVERSE REACTIONS ........................................................................................................ 1 Adverse Reaction Overview ................................................................................................
2 Clinical Trial Adverse Reactions ........................................................................................... 3 Less Common Clinical Trial Adverse Reactions....................................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data...................................................................................................................................... 5 Post-Market Adverse Reactions ..........................................................................................
20 9. DRUG INTERACTIONS ........................................................................................................ 2 Drug Interactions Overview.................................................................................................
3 Drug-Behavioral Interactions .............................................................................................. 4 Drug-Drug Interactions .......................................................................................................
5 Drug-Food Interactions...................................................................................................... 6 Drug-Herb Interactions .....................................................................................................
7 Drug-Laboratory Test Interactions .................................................................................... 277 10. CLINICAL PHARMACOLOGY ...........................................................................................
1 Mechanism of Action ...................................................................................................... 3 Pharmacokinetics ............................................................................................................
277 11. STORAGE, STABILITY AND DISPOSAL .............................................................................. 333 12. SPECIAL HANDLING INSTRUCTIONS................................................................................
34 13. PHARMACEUTICAL INFORMATION ............................................................................... 344 14. CLINICAL TRIALS ............................................................................................................
2 Comparative Bioavailability Studies................................................................................ 355 15. MICROBIOLOGY ............................................................................................................
355 16. NON-CLINICAL TOXICOLOGY .......................................................................................... 399 17. SUPPORTING PRODUCT MONOGRAPHS ........................................................................ 433 PATIENT MEDICATION INFORMATION ................................................................................
444 Bio-CIPROFLOXACIN Page 4 of 64 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS Bio-CIPROFLOXACIN (ciprofloxacin tablet) may be indicated for the treatment of patients with the following infections caused by susceptible strains of the indicated microorganisms: Respiratory Tract Infections Acute exacerbation of chronic bronchitis caused by: Haemophilus influenzae Moraxella catarrhalis Acute pneumonia caused by: Enterobacter cloacae Escherichia coli Haemophilus […]